Inside the New Hybrid Roles for Cell Therapy Clinical Trials with Immatics' Michael Mehler

We love to hear from our listeners. Send us a message.

Autologous cell therapy clinical trials and products are very complex, and the stakeholder investment is diverse. Immatics' Director, Clinical Operations, Michael Mehler, explains why new hybrid roles operate in clinical operations, clinical supply chain, strategic operations, and medical affairs to help bridge the gap between the sponsor company and the clinical site for clinical trials in an autologous setting. Mehler talks through the main aspects of a site operations lead and why the role is imperative to commercial success as well as how he sees the role evolving in the near term. He also explains what size CGT companies will benefit most from these new hybrid roles.

Cell & Gene: The Podcast is produced by Cell & Gene in partnership with Applied Biosystems by Thermo Fisher Scientific. 

Subscribe to the podcast!
Apple | Spotify | YouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn